<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00902915</url>
  </required_header>
  <id_info>
    <org_study_id>LD</org_study_id>
    <nct_id>NCT00902915</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Austrian Forum Against Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Austrian Forum Against Cancer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine efficacy of lenalidomide and dexamethasone in the
      treatment of patients with acute Myeloma (light chain)-induced renal failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the response rate (CR, VGPR, PR, MR, SD, and PD) To determine the renal response rate To determine the relation between category of myeloma response and improvement in GFR To determine the proportion of patients spared hemodialysis</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival, Event Free Survival, Overall Survival; Toxicity, evaluated according to the NCCN toxicity scale (type, frequency, severity, and relationship of adverse events to study treatment).</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma Light Chain Induced Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Lenalidomide - Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide plus dexamethasone</intervention_name>
    <description>peroral application; lenalidomide dosage according to severity grade of renal failure.</description>
    <arm_group_label>Lenalidomide - Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form.

          -  Age at least 18 years at the time of signing the informed consent form.

          -  MM (all stages) with acute light chain induced renal impairment

          -  Patients with previously unknown MM and acute light chain induced renal failure
             (GFR&lt;50ml/min and serum creatinine minimum 2.0 mg/dL) and with further workup
             revealing light chain induced renal injury with MM as underlying cause.

          -  Patients with previously established MM and normal renal function (GFR ≥60ml/min and
             serum creatinine ≤1.2mg/dl) with progressive disease and acute (within 6 weeks) light
             chain induced renal failure (GFR&lt;50ml/min and creatinine ≥ 2.0 mg/dL).

          -  Disease progression will be documented by one or more of the following criteria:

               -  Increase in serum paraprotein by &gt;25%, or increase of 50% of 24 hour urine
                  paraprotein excretion

               -  Hypercalcemia

               -  Progression of bone lesions

               -  Decrease in Hb&gt;2g/dl within 4 weeks (not induced by cytotoxic drugs)

               -  Increase in bone marrow plasma cell infiltration by &gt; 25%

          -  All previous medical anti-myeloma therapy (excluding corticosteroids) must have been
             discontinued at least 3 weeks prior to treatment in this study.

          -  Able to adhere to the study visit schedule and other protocol requirements.

          -  Measurable serum or urine paraprotein

          -  Laboratory test results within these ranges:

               -  Glomerular filtration rate &lt; 50ml/min

               -  Serum creatinine ≥ 2.0mg/dL

               -  Absolute leukocyte count ≥ 1.5 x 10G/L

               -  Platelet count minimum 75 x 10G/L if bone marrow plasma cell infiltration (BMPC)
                  is ≥50% or minimum 30 x 10G/L if BMPC infiltration is &lt;50%.

               -  Total bilirubin minimum 1.5 mg/dL

               -  AST (SGOT) and ALT (SGPT) not more than 2,5 x ULN

          -  Females of childbearing potential (FCBP) must:

               -  Understand that the study medication could have an expected teratogenic risk

               -  Agree to use, and be able to comply with, effective contraception without
                  interruption, 4 weeks before starting study drug, throughout study drug therapy
                  (including dose interruptions) and for 4 weeks after the end of study drug
                  therapy, even if she has amenorrhea. This applies unless the subject commits to
                  absolute and continued abstinence confirmed on a monthly basis. The following are
                  effective methods of contraception: Implant, Levonorgestrel-releasing
                  intrauterine system (IUS, Medroxyprogesterone acetate depot), Tubal
                  sterilization, Sexual intercourse with a vasectomised male partner only;
                  vasectomy must be confirmed by two negative semen analyses Ovulation inhibitory
                  progesterone-only pills (i.e., desogestrel)

               -  Agree to have a medically supervised pregnancy test with a minimum sensitivity of
                  25 mIU/ml not more than 3 days before the start of study medication once the
                  subject has been on effective contraception for at least 4 weeks. This
                  requirement also applies to women of childbearing potential who practice complete
                  and continued abstinence.

               -  Agree to have a medically supervised pregnancy test every 4 weeks including 4
                  weeks after the end of study treatment, except in the case of confirmed tubal
                  sterilization. These tests should be performed not more than 3 days before the
                  start of next treatment. This requirement also applies to women of childbearing
                  potential who practice complete and continued abstinence.

          -  Male subjects must:

               -  Agree to use condoms throughout study drug therapy, during any dose interruption
                  and for 28 days after cessation of study therapy if their partner is of
                  childbearing potential and has no contraception.

               -  Agree not to donate semen during study drug therapy and for 28 days after end of
                  study drug therapy.

          -  All subjects must agree not to share study medication with another person and to
             return all unused study drug to the investigator

          -  Disease free of prior malignancies for minimum of 3 years with exception of currently
             treated basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot; of the
             cervix or breast

          -  Agree to take low molecular weight heparin as prophylactic anticoagulation.

        Exclusion Criteria:

          -  Acute renal failure due to other causes than light-chain induced nephropathy such as
             NSAIRS, antibiotics, or other nephrotoxic drugs, or others.

          -  Acute renal failure due to hypercalcemia only, without excretion of nephrotoxic light
             chains.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Any prior use of lenalidomide

          -  Any anti-myeloma therapy within 3 weeks before day 1 of first cycle, with the
             exception of dexamethasone 40mg (maximum dose 160mg) or corticosteroid equivalent.

          -  Any other experimental drug or therapy within 3 weeks of baseline

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          -  Known positive for HIV or infectious hepatitis, type A, B or C or evidence of any
             severe active or chronic infection.

          -  Clinical significant heart disease (NYHA status&gt;2)

          -  Pregnant or breast feeding females

          -  Anamnesis of thromboembolic complications, such as stroke, myocardial infarction and
             pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>LKH Salzburg, 3rd Med. Dept.</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austrian Forum Against Cancer; 1st Med. Dept., Center for Hematology and Oncology, Wilhelminenspital, Montleartstrasse 37</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Wels-Grieskirchen, 4th Internal Dept.</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Brno and Faculty of Medicine MU</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University Prague</name>
      <address>
        <city>Prague</city>
        <zip>12821</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </location_countries>
  <removed_countries>
    <country>Slovakia</country>
  </removed_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2009</study_first_submitted>
  <study_first_submitted_qc>May 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2009</study_first_posted>
  <last_update_submitted>November 21, 2013</last_update_submitted>
  <last_update_submitted_qc>November 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma renal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

